TrialThe Lancet. Neurology2025

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.

Randall J Bateman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.